1 NAME OF THE MEDICINE
Indapamide hemihydrate

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each modified release tablet contains 1.5 mg of indapamide hemihydrate as the active ingredient.

Excipients with known effect:
Lactose monohydrate.
For the full list of excipients see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM
The tablets are white to off-white, round, biconvex, film coated.

4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of hypertension. It may be tried as a sole therapeutic agent in the treatment of hypertension. Normally, indapamide is used as the initial agent in multiple drug regimes.

4.2 DOSE AND METHOD OF ADMINISTRATION
Adults
One modified release coated tablet (1.5 mg indapamide hemihydrate) daily to be taken, by oral route, in the morning. The tablet should be swallowed whole and must not be chewed or crushed. The action of indapamide modified release tablets is progressive and whilst the optimum reduction in blood pressure is usually seen after four weeks, a further small but useful reduction in blood pressure may be observed over the following four to six weeks. A larger dose than one tablet of indapamide modified release daily is not recommended as there is little additional antihypertensive effect, whilst the diuretic effect becomes more pronounced.

A single daily tablet of indapamide modified release may effectively be combined with the following antihypertensive medicines: beta-blockers, methyldopa, clonidine, prazosin and ACE inhibitors.

Combination with a diuretic is not recommended as significant electrolyte disturbances may occur. Indapamide has a slight but significant carry-over hypotensive effect lasting up to 1 or 2 weeks after treatment is stopped.

4.3 CONTRAINDICATIONS
- Severe renal failure, anuria, progressive and severe oliguria.
- Hepatic coma, hepatic encephalopathy or severe impairment of liver function.
- Known hypersensitivity to indapamide, other sulphonamide derivatives, or any of the excipients (see section 6.1 List of excipients).
- Hypokalaemia.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Electrolyte changes observed with indapamide hemihydrate become more pronounced at doses above 1.5 mg modified release tablet/day. The daily maximum recommended dose of indapamide hemihydrate is 1.5 mg administered as one modified release tablet, since doses above this increase the diuretic effect and electrolyte disturbances without any further appreciable antihypertensive effect.

Hypokalaemia

Hypokalaemia may occur at all doses. Symptoms of hypokalaemia include weakness, cramps, and cardiac dysrhythmias. Hypokalaemia is a particular hazard in patients treated with digoxin as dangerous or fatal arrhythmias may be precipitated. Although indapamide can be safely administered to hypertensive patients with renal impairment, caution should be observed when it is administered to patients with severe renal impairment. In this case the unchanged drug is excreted primarily by the renal route, and plasma concentrations are elevated (see sections 5.1 Pharmacokinetic Properties and 4.4 Special warnings and precautions for use).

Uric acid

Hyperuricaemia may occur during treatment with indapamide, and gout has been reported rarely. Tendency to gout attacks may be increased in patients with hyperuricaemia.

Lithium

Diuretics should not be given with lithium because they reduce its renal clearance and add a high risk of lithium toxicity (see section 4.5 Interactions with other medicines and other forms of interactions).

Photosensitivity

Cases of photosensitivity reactions have been reported with thiazides and thiazide-related diuretics. It is recommended to stop treatment if a photosensitivity reaction occurs during treatment. If re-administration of the diuretic is deemed necessary, it is recommended that areas exposed to the sun or to artificial UVA are protected.

Lactose intolerance

Indapamide hemihydrate 1.5 mg modified release tablets contain lactose. Patients with an intolerance to lactose, rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Water and electrolyte balance

Patients receiving indapamide should be monitored for signs and symptoms of fluid or electrolyte imbalance; namely hyponatraemia, hypochloraemia and hypokalaemia. Blood urea, nitrogen and uric acid should also be assessed during treatment.

The signs of electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscle fatigue, hypotension, oliguria, gastrointestinal disturbances such as nausea and vomiting, tachycardia and ECG changes.

Plasma sodium

This must be measured before starting treatment, then subsequently at regular intervals as treatment with any diuretic may cause hyponatraemia, sometimes with very serious consequences. The decrease in plasma sodium may initially be asymptomatic. Regular monitoring is therefore essential and should be more frequent in the elderly and in patients with cirrhosis (see sections 4.8 Adverse effects (undesirable effects) and 4.9 Overdose). Hyponatraemia with hypovolaemia responsible for dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis.
Plasma potassium

Potassium depletion with hypokalaemia is the major risk of thiazide and related diuretics. The risk of onset of hypokalaemia (<3.4 mmol/L) must be prevented in certain high risk populations, i.e. the elderly, malnourished and/or polymedicated, cirrhotic patients with oedema and ascites, and patients with coronary artery disease and/or heart failure. In these patients, hypokalaemia increases the cardiac toxicity of digitalis preparations and increases the risk of arrhythmias. Hypokalaemia will be more common when combined with a steroid or adrenocorticotrophic (ACTH) treatment and when electrolyte intake is inadequate.

Individuals with a long QT interval, whether the origin is congenital or iatrogenic, are also at increased risk as hypokalaemia and bradycardia, are predisposing factors to the onset of severe arrhythmias, in particular, potentially fatal Torsades de pointes.

Plasma potassium should be measured in the first week of treatment. More frequent monitoring of plasma potassium is required in all the situations indicated above.

Hypokalaemia, if detected, should be corrected.

Plasma calcium

Diuretic treatment should be withdrawn before the investigation of parathyroid function. Thiazide and related diuretics may decrease urinary calcium excretion and cause a slight and transitory rise in calcium. Frank hypercalcaemia may be due to previously unrecognised hyperparathyroidism.

Use in hepatic impairment

Caution should be used when treating patients with severe hepatic disease to avoid metabolic alkalosis in cases of potassium depletion which may precipitate episodes of hepatic encephalopathy. Treatment with the diuretic must be stopped immediately if this occurs.

Orthostatic hypotension

Orthostatic hypotension may occur and may be potentiated by alcohol, barbiturates, narcotics or concurrent therapy with other antihypertensives.

When indapamide is combined with other non-diuretic antihypertensive medicines, the effects on blood pressure are additive.

Sulphonamide derivatives have been reported to exacerbate or activate systemic lupus erythematosus. Serious allergic skin reactions (such as Stevens-Johnson syndrome) have also occasionally been reported with sulphonamides. This should be considered when using indapamide.

Although indapamide can be used safely in patients with hypertension impairment, treatment should be discontinued if there is an increase in azotaemia and oliguria.

Use in renal impairment

Although indapamide can be used safely in patients with renal impairment, treatment should be discontinued if there is an increase in azotaemia and oliguria.

A study in patients with impaired renal function demonstrated that patients with severe renal impairment (creatinine clearance 11-35 mL/min) had impaired clearance of indapamide and elevated plasma levels of the drug.

Blood glucose

Monitoring of blood glucose is important in patients with diabetes, in particular in the presence of hypokalaemia.

Athletes
This medicinal product contains indapamide which may give a positive reaction in doping tests.

**Use in the elderly**

In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with indapamide when renal function is normal or only minimally impaired.

**Paediatric use**

Safety and effectiveness have not been established.

**Effects on laboratory tests**

No data available.

**Laboratory test results**

Hyperuricaemia (0.4%). Hypoglycaemia (0.4%) (see section 4.8 Adverse effects (Undesirable effects)).

4.5 **INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

No interactions have been reported between indapamide and anticoagulants, or between indapamide and uricosuric medicines. It is recommended that the drug not be used in combination with a diuretic since the combination may cause hypokalaemia and hyperuricaemia.

**Combinations that are not recommended:**

**Lithium:**

The combined use of indapamide and lithium may result in increased plasma lithium levels and symptoms of overdose (due to decreased urinary lithium excretion). If diuretics are necessary, careful monitoring of plasma lithium and dose adjustment are required.

**Combined use which requires special care:**

**Torsades de pointes-inducing drugs:**

The combined use of indapamide and Torsades de pointes-inducing drugs, including the following, is not recommended due to the increased risk of ventricular arrhythmias, particularly Torsades de pointes (hypokalaemia is a risk factor):

- class Ia antiarrhythmics (e.g. disopyramide)
- class III antiarrhythmics (e.g. amiodarone, sotalol)
- some antipsychotics: phenothiazines (e.g. trifluoperazine), benzamides (e.g. amisulpride, sulpiride) and butyrophenones (e.g. droperidol, haloperidol)
- others: diphenamid, erythromycin IV, pentamidine, moxifloxacin.

Monitor (using plasma electrolytes and ECG) for hypokalaemia and correct, if required, before using indapamide and a Torsades de pointes-inducing drug in combination.

**NSAIDs (systemic route) including COX-2 selective inhibitors, high dose salicylic acid (≥ 3 g/day):**

Due to the risk of acute renal failure in patients with dehydration as a result of decreased glomerular filtration, it is recommended that hydration and renal function be monitored at the start of treatment.
Combined use with NSAIDs may also result in a reduction in the antihypertensive effect of indapamide.

**Angiotensin converting enzyme (ACE) inhibitors:**

Combined use with ACE inhibitors in the presence of pre-existing sodium depletion (particularly in patients with renal artery stenosis) may increase the risk of sudden hypotension and/or acute renal failure.

In patients with hypertension when prior diuretic treatment may have caused sodium depletion, it is necessary to either:

- stop the diuretic three days before starting treatment with the ACE inhibitor, and restart a hypokalaemic diuretic if necessary; or
- give low initial doses of the ACE inhibitor and increase the dose gradually.

In patients with congestive heart failure, initiation with a very low dose of ACE inhibitor, possibly after a reduction in the dose of the hypokalaemic diuretic, is recommended.

The monitoring of renal function (plasma creatinine) during the first weeks of treatment with an ACE inhibitor is recommended in all patients.

**Other compounds causing hypokalaemia: amphotericin B (IV), gluco- and mineralo-corticoids (systemic route), stimulant laxatives:**

Due to the increased risk of hypokalaemia (additive effect):

- monitoring, and correction if required, of plasma potassium (especially during treatment with digoxin) is recommended
- the use of non-stimulant laxatives is recommended.

**Baclofen:**

Due to the increased risk of antihypertensive effects, it is recommended that hydration and renal function be monitored at the start of treatment.

**Digoxin:**

Monitoring of plasma potassium and ECG is recommended due to the increased risk of hypokalaemia following co-administration of indapamide and digoxin.

**Allopurinol:**

Combined use with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.

**Combinations to be taken into consideration:**

**Potassium-sparing diuretics (amiloride, spironolactone, triamterene):**

Due to the increased risk of either hyperkalaemia or hypokalaemia (particularly in patients with renal failure or diabetes), care should be taken when co-administering potassium-sparing diuretics. Plasma potassium and ECG should be monitored and, if necessary, treatment reviewed.

**Metformin:**

Do not co-administer with metformin when plasma creatinine exceeds 15 mg/L (135 μmol/L) in men and 12 mg/L (110 μmol/L) in women due to the increased risk of metformin induced lactic acidosis as a result of the possibility of functional renal failure associated with diuretics and more particularly with loop diuretics.

**Iodinated contrast media:**
Adequate hydration before administration of the iodinated compound is recommended due to an increased risk of acute renal failure resulting from dehydration, particularly when large doses of iodinated contrast media are used.

Imipramine-like antidepressants, neuroleptics:
Caution is recommended with these combinations due to an increased antihypertensive effect and increased risk of orthostatic hypotension.

Calcium (salts):
Caution is recommended with this combination due to the risk of hypercalcaemia resulting from decreased urinary elimination of calcium.

Cyclosporin, tacrolimus:
Caution is recommended with this combination due to the risk of increased plasma creatinine without any change in circulating cyclosporin levels, even in the absence of water/sodium depletion.

Corticosteroids, (systemic route):
Caution is recommended with this combination due to the risk of decreased antihypertensive effect (water/sodium retention due to corticosteroids).

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility
A reproduction study in rats showed no impairment of male or female fertility at oral indapamide doses up to 25mg/kg/day, however, the number of implantation sites was reduced at the highest dose.

Use in pregnancy (Category C)
Indapamide should be avoided in pregnant women and should not be used to treat oedema in pregnancy.

There are limited data with the use of indapamide in pregnant women. Prolonged exposure to thiazides during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause foetal-placental ischaemia and growth retardation.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

Thiazides, related diuretics and loop diuretics enter the foetal circulation and may cause electrolyte disturbances. Neonatal thrombocytopenia has been reported with thiazides and related diuretics. Loop diuretics like furosemide and bumetanide are probably also associated with this risk. During the latter part of pregnancy, medicines of this type should be used with caution, and at the lowest effective dose.

Use in lactation
Indapamide should not be used during breast-feeding. Indapamide is excreted in human breast milk and the possible effect on the newborn is unknown and cannot be excluded. Indapamide is closely related to thiazide diuretics which have been associated with decrease in, or even suppression of, lactation. Hypersensitivity to sulphonamide-derived medicines and hypokalaemia might occur.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Indapamide does not affect vigilance but different reactions related to a decrease in blood pressure may occur in individual cases, especially at the start of treatment or when another
antihypertensive agent is added. Treatment with any blood pressure lowering agent may, therefore, affect the ability to drive, cross the road safely or operate machinery.

4.8 ADVERSE EFFECTS (UNDISIRABLE EFFECTS)

In general, most adverse effects are mild and transient. The most frequently reported are: hypersensitivity reactions, mainly dermatological (in subjects with a predisposition to allergic and asthmatic reactions and macropapular rashes), asthenia, dizziness, headache, fatigue, muscle cramps and gastrointestinal disturbances. These usually occur within the first month of treatment.

During clinical trials, hypokalaemia (plasma potassium <3.4 mmol/L) was seen in 10% of patients and <3.2 mmol/L in 4% of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.23 mmol/L.

The majority of adverse reactions concerning clinical or laboratory parameters are dose-dependent. Other adverse reactions have been non-specific. Cutaneous rash and impotence have been occasionally reported. Percentages shown below indicate the incidence in clinical trials.

The following undesirable effects have been observed with indapamide during treatment ranked according to the following frequencies:

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse Effects</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and the Lymphatic System Disorders</td>
<td>Agranulocytosis</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Leucopaenia</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia</td>
<td>Very rare</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Hypercalcaemia</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Potassium depletion with hypokalaemia, particularly serious in certain high risk populations (see sections 4.3 Contraindications and 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Hyponatraemia† (see section 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Vertigo</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>Common</td>
</tr>
<tr>
<td>MedDRA System Organ Class</td>
<td>Adverse Effects</td>
<td>Frequency</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Paresthesia</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Syncope§</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Dizzinessness</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Sleepiness</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Weakness</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Visual Disturbance</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Myopia§</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Blurred vision§</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Visual impairment</td>
<td>Not known</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td>Arrhythmia</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Torsade de pointes (potentially fatal) § (see sections 4.3 Contraindications and 4.5 Interactions with other medicines and other forms of interactions)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Palpitations</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Chest pain</td>
<td>Very rare</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>Hypotension</td>
<td>Very rare</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Vomiting</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Dyspepsia</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Dry mouth</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Pancreatitis</td>
<td>Very rare</td>
</tr>
<tr>
<td>Hepato-biliary Disorders</td>
<td>Abnormal hepatic function</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Possibility of onset of hepatic encephalopathy in case of hepatic insufficiency§ (see section 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Hepatitis§</td>
<td>Not known</td>
</tr>
<tr>
<td>Skin and Subcutaneous</td>
<td>Hypersensitivity reactions, mainly</td>
<td>Common</td>
</tr>
<tr>
<td>MedDRA System Organ Class</td>
<td>Adverse Effects</td>
<td>Frequency</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Tissue Disorders</td>
<td>dermatological, in subjects with a predisposition to allergic and asthmatic reactions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maculopapular rashes</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Purpura</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Pruritis</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Angioedema</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Urticaria</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Toxic epidermic necrolysis</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Stevens Johnson Syndrome (see section 4.4 Special warnings and precautions for use)</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Possible worsening of pre-existing acute disseminated lupus erythematosus§</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Cases of photosensitivity reactions§ have been reported (see section 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td>Musculoskeletal Disorders</td>
<td>Muscle cramps</td>
<td>Common</td>
</tr>
<tr>
<td>Renal and Urinary Disorders</td>
<td>Renal failure</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Cystitis</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Investigations</td>
<td>Electrocardiogram QT prolonged§ (see sections 4.4 Special warnings and precautions for use and 4.5 Interactions with other medicines and other forms of interactions)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Blood glucose§§ increased during treatment (see section 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Blood uric acid§§ increased during treatment (see section 4.4 Special warnings and precautions for use)</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Elevated liver enzyme levels§</td>
<td>Not known</td>
</tr>
</tbody>
</table>

1Reported in clinical studies with the immediate release formulation of indapamide, and not seen in the indapamide SR studies.
2Reported for indapamide as a Post-Marketing Adverse Effect.
Appropriateness of treatment with indapamide SR must be very carefully weighed in patients with gout or diabetes.

Other adverse reactions, reported in clinical studies with the immediate release formulation of indapamide, and not seen in indapamide modified release studies, include the following:

**Central Nervous System**: lethargy.

**Gastrointestinal**: anorexia, gastralgia, diarrhoea.

**Metabolism and nutrition disorders**: hypochloraemia, hyponatraemia.

**Musculoskeletal**: joint pain, back pain, weakness of legs.

**Cardiac disorders**: tachycardia, ECG changes (non specific ST-T changes, U waves, left ventricular strain).

**Urogenital**: modification of libido, polyuria.

**Vascular disorders**: orthostatic hypotension.

**Endocrine**: gout.

**Other**: tinnitus, malaise/fainting, sweat.

**Laboratory abnormalities**: BUN increase, blood creatinine increase.

### Reporting suspected adverse effects


### 4.9 OVERDOSE

#### Symptoms

Signs of acute poisoning at higher doses take the form of water/electrolyte disturbances (hyponatraemia, hypokalaemia) and may include the possibility of nausea, vomiting, hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria possibly to the point of anuria (by hypovolaemia). In patients with cirrhosis, an overdose might precipitate hepatic coma.

#### Treatment

There is no specific antidote. Treatment is symptomatic and supportive. Discontinue drug; induce emesis or perform gastric lavage and/or administration of activated charcoal (Activated charcoal may reduce absorption of the medicine if given within one or two hours after ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected), correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).
5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Indapamide is an oral antihypertensive medicine. The mechanism whereby indapamide exerts its antihypertensive action has not been completely elucidated; both vascular and renal actions have been implicated. The possible beneficial pharmacological effects of indapamide in the treatment of hypertension include a reduction in cardiac hypertrophy and a reduction in the thickening of arterial walls, a prevention of the accumulation of the embryonic isoform of fibronectin in coronary vessels, free radical scavenging leading to stimulation of vasodilator eicosanoid formation, and interaction with renal carbonic anhydrase.

The renal effects of indapamide is minimal and the antihypertensive effect of indapamide has been attributed to a reduction in vascular reactivity to pressor amines. The finding that indapamide retains its antihypertensive activity in patients who are functionally anephric lends support to this hypothesis.

The renal site of action of indapamide is the proximal segment of the distal tubule. Indapamide appears to have natriuretic properties (sodium and chloride being excreted in equivalent amounts) with less effect on kaliuresis or uric acid excretion. Only at doses greater than 1.5 mg indapamide hemihydrate modified release tablet/day is an appreciable increase in urinary volume observed in man. No significant changes in plasma sodium levels have been observed in clinical studies. Significant hypokalaemia (plasma potassium < 3.2 mmol/L) has been reported in 4% of patients.

Indapamide does not adversely affect serum triglycerides, LDL cholesterol, the LDL-HDL cholesterol ratio, or glucose tolerance.

Clinical trials

No data available.

5.2 PHARMACOKINETIC PROPERTIES

Indapamide is supplied in a modified release dose based on a matrix system in which the active ingredient is dispersed in a support which allows modified release of indapamide. The kinetics of indapamide are linear.

Absorption

The fraction of indapamide released is rapidly and totally absorbed via the gastrointestinal digestive tract. Ingestion with food slightly increases the rate and extent of absorption. These changes are unlikely to be clinically significant. Peak serum level following a single dose occurs about 12 hours after ingestion, repeated administration reduces the variation in serum levels between two doses.

Distribution

Indapamide is widely distributed throughout the body, with extensive binding to specific sites. In blood, it is highly bound to red blood cells (80%) and, more specifically, to carbonic anhydrase (98%) without having any significant inhibiting activity on this enzyme.

Binding of indapamide to plasma proteins is 79%. The plasma elimination half-life is 14 to 24 hours (mean 18 hours). The drug has a volume of distribution of approximately 60 L. Steady state is achieved after 7 days. Repeated administration does not lead to accumulation.
Metabolism

The drug is extensively metabolised in the liver, with only 5 to 7% of the dose excreted in the urine as unchanged drug. Elimination is essentially urinary (70% of the dose) and faecal (22%) in the form of inactive metabolites.

High risk individuals

In patients with severe renal impairment, plasma concentrations sometimes increase significantly.

Excretion

No data available.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Indapamide was negative in mutagenicity tests in bacteria and bone marrow micronucleus tests in mice. There was a decrease in weight gain of the F1 generation from rats treated orally at 2.5 mg/kg/day. Galactopoiesis was affected in the F1 generation from rats treated orally at 0.5 mg/kg/day and this led to increased mortality of the F2 generation during the first 48 hours of life. No embryo-foetal toxicity or teratogenic potential were seen in rats (up to 150 mg/kg/day) and in rabbits (up to 180 mg/kg/day).

Carcinogenicity

Carcinogenicity studies in mice and rats showed no evidence of tumourigenicity when indapamide was administered in the diet at levels up to 100 mg/kg/day.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

- lactose monohydrate
- povidone
- hypromellose
- colloidal anhydrous silica
- magnesium stearate
- polyvinyl alcohol
- macrogol
- titanium dioxide
- purified talc

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine. See section 4.5 Interactions with other medicines and other forms of interactions.
6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

6.5 NATURE AND CONTENTS OF CONTAINER

APO-INDAPAMIDE SR indapamide hemihydrate 1.5 mg modified release tablet blister pack (AUST R 208007):

Clear PVC/Aluminium foil blister containing 10, 30 and 90 tablets.

Not all pack sizes may be available.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Indapamide hemihydrate is a non-thiazide indole derivative of chlorosulphonamide. The active ingredient is a racemic mixture. Indapamide is a white crystalline lipophilic powder, soluble in methanol, ethanol, acetic acid and ethyl acetate, very slightly soluble in ether, chloroform and benzene and practically insoluble in water.

Chemical structure

![Chemical structure](image)

Chemical Name: 4-chloro-N-(2-methyl-1-indolinyl)-3- sulfamoyl benzamide hemihydrate.

Molecular Formula: $C_{16}H_{16}ClN_3O_3S$, $\frac{1}{2}H_2O$

Molecular weight: 374.85.

CAS number

26807-65-8

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park
9 DATE OF FIRST APPROVAL
7 May 2014

10 DATE OF REVISION
28 November 2019

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>Warning added for ‘Use in elderly’ section. New section ‘Laboratory investigations’ added for test results.</td>
</tr>
<tr>
<td>4.8</td>
<td>Adverse event Hyponatraemia added for Metabolism and Nutrition Disorders section in table.</td>
</tr>
</tbody>
</table>